Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol

Adjuvant breast cancer therapy containing anthracyclines with or without anti–human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with cancer treatment–related cardiac dysfunction. In the PRADA trial (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Heck, Siri Lagethon, Mecinaj, Albulena, Ree, Anne Hansen, Hoffmann, Pavel, Schulz-Menger, Jeanette, Fagerland, Morten Wang, Gravdehaug, Berit, Røsjø, Helge, Steine, Kjetil, Geisler, Jürgen, Gulati, Geeta, Omland, Torbjørn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212877/
https://www.ncbi.nlm.nih.gov/pubmed/33993702
http://dx.doi.org/10.1161/CIRCULATIONAHA.121.054698

Ejemplares similares

Ejemplares similares